title: Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders.
abstract: OBJECTIVE
  To determine if the Beliefs about Medicines Questionnaire (BMQ) has satisfactory psychometric properties in patients with severe mental disorders and if their scores differ from those of patients with severe medical disorders. To investigate if the scores are related to medication adherence.
  
  
  METHODS
  Two hundred and eighty psychiatric patients completed the BMQ and reported how much of their medication they had taken the past week. Serum concentrations of medications were analyzed. BMQ scores were compared with those of patients with chronic medical disorders.
  
  
  RESULTS
  Cronbach's alpha was satisfactory for all subscales. The psychiatric group scored lower on the necessity of taking medication than the medical group. Non-adherent patients felt medication to be less necessary and were more concerned about it than adherent patients. The necessity subscale predicted adherence fairly well.
  
  
  CONCLUSIONS
  The BMQ has satisfactory psychometric properties for use in patients with severe mental disorders. The constructs measured by the BMQ are related to adherence in these patients.
authors.affiliation: Division of Psychiatry, Ulleval University Hospital & Institute of Psychiatry, University of Oslo, Oslo, Norway. halldora.jonsdottir@medisin.uio.no
authors.forename: H
authors.initials: H
authors.lastname: Jónsdóttir
authors.forename: S
authors.initials: S
authors.lastname: Friis
authors.forename: R
authors.initials: R
authors.lastname: Horne
authors.forename: K I
authors.initials: KI
authors.lastname: Pettersen
authors.forename: A
authors.initials: A
authors.lastname: Reikvam
authors.forename: O A
authors.initials: OA
authors.lastname: Andreassen
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology*; D003430:Cross-Sectional Studies; D003469:Culture; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009664:Norway; D010349:Patient Compliance / Q000523:psychology*; D011594:Psychometrics; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D011795:Surveys and Questionnaires
chemical_list: D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D016651:Lithium Carbonate